Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
NCT05024266Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in squamous cell carcinoma of the lung (LSCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT05024266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024266.